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Abstract: Noncommunicable diseases (NCDs) account for a grow-
ing burden of morbidity and mortality among people living with HIV
in low- and middle-income countries (LMICs). HIV infection and
antiretroviral therapy interact with NCD risk factors in complex ways,
and research into this “web of causation” has so far been largely based
on data from high-income countries. However, improving the under-
standing, treatment, and prevention of NCDs in LMICs requires
region-speciﬁc evidence. Priority research areas include: (1) deﬁning
the burden of NCDs among people living with HIV, (2) understanding
the impact of modiﬁable risk factors, (3) evaluating effective and
efﬁcient care strategies at individual and health systems levels, and
(4) evaluating cost-effective prevention strategies. Meeting these needs
will require observational data, both to inform the design of random-
ized trials and to replace trials that would be unethical or infeasible.
Focusing on Sub-Saharan Africa, we discuss data resources currently
available to inform this effort and consider key limitations and meth-
odological challenges. Existing data resources often lack population-
based samples; HIV-negative, HIV-positive, and antiretroviral ther-
apy–naive comparison groups; and measurements of key NCD risk
factors and outcomes. Other challenges include loss to follow-up,
competing risk of death, incomplete outcome ascertainment and mea-
surement of factors affecting clinical decision making, and the need to
control for (time-dependent) confounding. We review these challenges
and discuss strategies for overcoming them through augmented data
collection and appropriate analysis. We conclude with recommenda-
tions to improve the quality of data and analyses available to inform
the response to HIV and NCD comorbidity in LMICs.
Key Words: HIV/AIDS, Sub-Saharan Africa, resource limited set-
tings, casual inference, loss to follow-up, cohorts
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INTRODUCTION
HIV disease has one necessary cause: infection by HIV.
In contrast, many chronic noncommunicable diseases
(NCDs), including heart disease, cancer, and chronic pulmo-
nary disease result from the interaction of multiple risk
factors, such as smoking, nutrition, physical activity, and
genetics.1 In high-income countries (HICs), many behavioral
risk factors occur more commonly in HIV-positive than HIV-
negative populations. For example, the prevalence of smoking
is considerably higher in people with HIV than in the general
population.2,3 Further, both HIV virus itself and antiretroviral
(ARV) drugs used to treat the infection may interact with
traditional risk factors to cause NCDs.4 For example, HIV-
induced immune activation leads to inﬂammation and macro-
phage recruitment, which in turn is associated with aging,
atherosclerosis and cardiovascular disease, and cancer.5–11
Some ARVs increase levels of low-density lipoprotein cho-
lesterol or reduce insulin sensitivity of peripheral tissues—
risk factors also inﬂuenced by diet and physical activity.4,12
Adherence to antiretroviral therapy (ART) affects virologic
response and thus immune activation and is in turn associated
with lifestyle and psychosocial NCD risk factors.13,14 Figure 1
illustrates how these complex interactions contribute to car-
diovascular disease. Similar causal relationships occur for
many other NCDs, including diabetes, liver disease, chronic
kidney disease, depression, and a wide range of can-
cers.6,10,11,15–18
Research to date supporting this complex “web of cau-
sation” has largely been based on data from HICs. Many
causal relationships documented in these countries, such as
the inﬂammatory effects of HIV or potential toxicity of cer-
tain ARVs, likely also exist in low- and middle-income
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countries (LMICs). However, the magnitude of these effects
may differ in LMICs due to differing distributions of comor-
bidities, coinfections, HIV subtypes, and NCD risk factors.
LMICs may also differ in their use of more toxic ARVs, and
the extent to which NCD risk factors differ between HIV-
positive and HIV-negative individuals.12,19 Improving the
understanding, treatment, and prevention of HIV and NCDs
in LMICs thus requires region-speciﬁc evidence.
Available evidence is insufﬁcient to tackle the challenge
of NCDs in the HIV-uninfected population in LMICs and is
even more limited for the large number of people living with
HIV (PLHIV) in these countries. Priority research areas in the
HIV-positive population include: (1) deﬁning the burden of
NCDs today and in decades to come, (2) understanding the
prevalence and importance of modiﬁable risk factors, (3)
evaluating effective and efﬁcient treatment and care strategies
at the individual and health systems levels, and (4) evaluating
cost-effective preventive interventions.19
Meeting these needs poses signiﬁcant methodological
challenges. Randomized trials will at most allow us to assess
the efﬁcacy of a limited number of interventions, and while
innovative designs can expand the number of questions
amenable to study using randomization,20,21 many exposures,
such as HIV infection itself and access to ART cannot ethi-
cally be randomized. Improving prevention and treatment of
NCDs in LMICs thus requires us to make the best possible
use of observational data. However, because of the complex
web of causation of NCDs, disentangling causal effects from
confounding or mediating associations in such data is difﬁcult.22
In this article, we review data resources currently available to
inform this effort, focusing on longitudinal observational data
from Sub-Saharan Africa (SSA). We then consider key meth-
odological challenges posed by these data and how these chal-
lenges can be overcome through augmented data collection and
appropriate analysis.
SEARCH STRATEGY
We searched the PubMed database with no language or
date speciﬁed to identify sources of and gaps in currently
available data on NCDs and HIV in SSA and other lower-
income settings. We combined MESH and free-text terms
describing HIV infection, NCDs, and lower-income settings.
For example, we combined [HIV infections (Mesh) or HIV or
AIDS or immunodeﬁciency virus] with [neoplasms (Mesh) or
neoplasms or cancer] and [Africa (Mesh) or Africa or Africa*
or developing countries (Mesh)]. We used our collections of
methodological articles and performed additional searches to
identify relevant articles on the methodological challenges
discussed in the article and regularly referred to the reviews
in the current special issue.
EXISTING DATA RESOURCES AND
THEIR LIMITATIONS
The massive scale-up of ART and the evaluation and
implementation research that has informed it means that large
cohort studies and clinical databases of PLHIV on ART are
now available. For example, the International epidemiological
Databases to Evaluate AIDS (IeDEA) has assembled data
from almost 1 million patients receiving ART across Africa to
address clinical and operational research questions around the
delivery of ART and clinical outcomes in children, adoles-
cents, and adults.23–25 Similar IeDEA consortia are providing
clinical data from the Americas and Asia.26,27 The IeDEA data
and those collected by other organizations, such as the Inter-
national Center for AIDS Care and Treatment Programs
(ICAP)28,29 or Médecins Sans Frontières (MSF)30,31 reﬂect
routine care across a wide range of care settings, including
large and small urban and rural clinics run by national health
systems or nongovernmental organizations.
FIGURE 1. Interactions among HIV
infection, ART, and different risk
factors in cardiovascular disease risk.
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There is, however, a dearth of data on NCDs and their
risk factors in the HIV-positive population in SSA. In clinical
cohort consortia such as IeDEA, data on NCD risk factors and
outcomes are not routinely collected, and there are few ART-
naive patients with extended follow-up. Further, these data
sources include no comparable HIV-negative groups.
A recent systematic review of the African Partnership for
Chronic Disease Research (APCDR) on cardiovascular risk
factors in populations in SSA identiﬁed 52 studies, but not
a single cohort study that included ART-naive HIV-positive
patients and HIV-negative persons.32 Further, most studies
were cross-sectional and based on clinic populations, posing
limitations we discuss further below.
Although over 200 Demographic and Health Surveys
(DHSs) have been done in general populations since 1985,
including over 100 in SSA, the focus of these surveys has
generally been on fertility, contraception, and maternal and
child health, with no data collected on NCDs.33 One excep-
tion is the Agincourt Health and Demographic Surveillance
System in rural northeast South Africa, which has collected
data on both HIV status and NCD risk factors for several
years.34 Other DHSs are planning to include NCD risk factors
in the future.35,36 Surveys using the WHO STEP-wise
approach to Surveillance (STEPS) for chronic disease risk
factors do not generally test for HIV infection.37 This was
the case, for example, in a recent nationwide STEPS survey
in Malawi.38 One notable exception are the STEPS surveys
done in rural KwaZulu-Natal, South Africa, within the frame-
work of longitudinal population-based HIV and health sur-
veillance conducted by the Africa Centre for Health and
Population Studies.39,40 Table 1 details typical characteristics
of some of the available data and discusses their limitations.
Existing data sources from LMICs therefore pose
signiﬁcant challenges for the study of NCDs and HIV
comorbidity, including a lack of population-based samples;
absence of HIV-negative, HIV-positive, and ART-naive com-
parison groups; and incomplete measurement of key NCD risk
factors and outcomes. Further, studies of NCDs in PLHIV
confront a set of challenges shared by studies of PLHIV in
LMICs more generally, including loss to follow-up, incomplete
outcome ascertainment, incomplete measurement of key
factors affecting clinical decision making, and the need to
control for (time-dependent) confounding and validate prog-
nostic models. We review each of these challenges below.
CHALLENGES AND OPPORTUNITIES FOR HIV
AND NCD RESEARCH
Clinic Versus Population-based Samples
Although useful for some questions, clinic-based cohorts
have signiﬁcant limitations when the goal is to characterize the
underlying population. Differences between those in care and
the underlying population may be particularly pronounced in
observational studies of NCDs in LMICs for several reasons.
First, the socio-demographic characteristics of PLHIV in care
differ in important ways from those who are not in care. For
example, men, those of lower income and those in more rural
areas may be underrepresented in clinical settings.44 Because
risk of NCDs also differs by sex, income, and rural versus
urban lifestyles,45,46 use of a clinic-based sample may cause
studies to underestimate or overestimate the disease burden
posed by NCDs at the population level and to underestimate
or overestimate the importance of speciﬁc NCD risk factors.
Individuals with more recent infection and better treatment are
further overrepresented among cohorts based on patients alive
and in care.47
Second, many clinics only provide care to PLHIV and
are thus unable to identify appropriate HIV-negative com-
parator samples. Disentangling the effects of HIV infection on
NCD incidence from associations due to confounding
requires comparisons with demographically and behaviorally
similar uninfected individuals. For example, in HICs, smok-
ing, alcohol, and HCV and HBV coinfection are more
common among PLHIV. Unless appropriately accounted
for, these factors can result in overestimates of the association
between HIV infection and a wide range of cancers, liver
disease, and neurocognitive disorders.10,15,18 In LMICs, both
magnitudes of such confounding and the key confounding
variables may differ because of differences in HIV risk fac-
tors. Ideally, HIV-negative comparators would be drawn from
the same population as their HIV-positive counterparts.
Third, clinic-based cohorts generally provide limited
longitudinal follow-up of ART-naive patients, particularly those
with high CD4 counts. Further, patients entering routine clinical
care early in the course of HIV disease are likely to differ in
important ways from those entering care later. Population-based
samples using community-wide HIV testing are thus essential
for providing adequate ART-naive comparison groups.
For some research questions, clinic-based cohorts pro-
vide an excellent data source. In particular, clinic-based
samples are appropriate for analyses that aim to understand
and improve clinical outcomes among patients in care.
Clinical data systems can be leveraged to measure rich
longitudinal data, including on diagnostic tests, routine
laboratory monitoring, medication use, and physical ﬁndings.
Such data are crucial for analyses aimed at developing and
evaluating individual and health service level strategies for
treatment and care. Examples include developing and eval-
uating thresholds for intervening on metabolic abnormalities,
strategies for modifying ART regimens to prevent alcohol-
associated liver disease, adjuvant therapies for the treatment
of HIV-associated nephropathy, and strategies for integrated
service delivery on a wide range of NCDs.15,17,18,48 However,
realizing this potential requires that diagnostic tests, labora-
tory monitoring, and medications for treating both HIV and
NCDs be available in clinics, and that their indications and
use be reliably captured by data systems.
Loss to Follow-up, Competing Risks, and
Incomplete Outcome Ascertainment
In SSA, and in many LMICs in other regions, failure to
retain PLHIV in care undermines the individual and public
health beneﬁts of ART delivery programs. In Africa, loss to
follow-up after enrollment often reaches 20%–40% after 2
years.49–52 High rates of loss to clinic and incomplete outcome
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ascertainment also threaten program monitoring and public
health evaluations including NCD research.53–60
Patients maintained under observation are generally
not representative of the entire patient cohort because risk
factors for mortality and NCDs, such as male gender and
age, are also associated with the probability of being lost
to clinic.61–64 Most analytic methods to reduce bias
because of differential loss rely on the frequently unreal-
istic assumption that outcomes among patients remaining
in care are representative of outcomes among patients
with similar characteristics who are lost. This assumption
breaks down entirely if loss to follow-up is a direct con-
sequence of the unmeasured outcome, posing a particular
challenge in African settings, where death accounts for
12%–87% of patients lost to follow-up.53,55 Studies in
which vital status information on patients lost to follow-
up was obtained, for example, through linkage with the
national death registry in South Africa,58 or through trac-
ing a random sample of lost patients in Uganda,55 have
highlighted the potential for incomplete death ascertain-
ment to dramatically bias estimates of risk and predictors
of mortality.54,62,63
TABLE 1. Examples of Potential Resources for Research on NCDs in HIV-Positive Populations in LMICs
Type of Study Example Limitations
Community-based
longitudinal studies
The GPC was set up in 1989 to study HIV in rural
Southwestern Uganda. The annual surveys were
extended in 2010 to collect data on lifestyle factors
(smoking, alcohol, physical activity, and diet), blood
pressure, and waist and hip circumference; to measure
HbA1c and lipid factors; and to perform genetic tests.
The 2010/11 survey round included a total of 15,376
persons (80.2% of all eligible), with about 90% of the
study population below 50 years of age and an HIV
prevalence of 9% among those aged 15–49 yrs41
The number of HIV-positive study participants will
depend on the HIV prevalence and availability of
ART but will typically be relatively small. Detailed
data on ART may not be available. The study
population will need to be observed for many years
and loss to follow-up may be a problem
Routine clinical
databases and cohorts
The IeDEA are a global consortium of ART programs in
48 countries and contain data on currently almost 1
million patients.23 Patients are included as they initiate
HIV care at a participating clinic. Data are collected at
baseline and each follow-up visit, including the type
of ART initiated, and, where available, CD4 counts
and HIV-1 plasma RNA levels23
NCD risk factors and outcomes are not generally
assessed in routine care cohorts and clinical databases
of patients on ART. Factors such as loss to follow-up
and incomplete engagement in care are often
substantial. Most study participants are HIV-positive
and most are on ART
Cross-sectional DHSs The Malawi 2010 DHS was based on a 2-stage stratiﬁed
sample of 18,000 ever-married women aged 12–49
yrs.42 In a subsample of ever-married men aged 15–54
yrs who were also interviewed, a group was selected
to participate in blood pressure measurements,
hemoglobin and blood glucose testing, and height and
weight measurements
The DHS evolved from the world fertility and
contraception surveys in the 1970s, and the focus
continues to be on maternal and child health.33
Limitations include the cross-sectional nature of the
data, the lack of information on risk factors for NCDs,
limited or no HIV testing, and the restriction to
younger populations
WHO STEPS surveys A population-based cross-sectional survey was
conducted in the Malawian population aged 25–64
yrs,38 using the WHO STEP-wise approach to chronic
disease risk factor Surveillance (STEPS)37; a total of
5451 individuals were randomly selected. Data
collection was in 3 steps: a questionnaire on
demographic and lifestyle data (step 1, 95% had
questionnaire data), measurements of height, weight,
blood pressure, waist and hip circumference (step 2,
75% had blood pressure measured), and measurement
of total cholesterol and fasting blood glucose (step 3,
50% had cholesterol measured)
Limitations include the cross-sectional nature of the
survey and the lack of information on the HIV status
of participants




SEARCH is a cluster randomized trial to evaluate HIV
prevention, health, and economic impacts of expanded
HIV testing and ART initiation at all CD4 counts,
compared with ART delivered according to in-country
guidelines. SEARCH will enroll approximately
320,000 individuals (150,000 adults) from 32
communities in Uganda and Kenya. Blood pressure,
alcohol intake, random blood glucose, and HIV
antibody will be measured longitudinally in
population-based cohorts that include both HIV+ and
HIV2 residents, and measurements will be linked to
clinical records. Height and weight will also be
measured among children43
Although the population size is large, follow-up time is
currently planned for 5 yr only, preventing
investigation of longer-term ART effects
DHS, Demographic and Health Surveys; GPC, General Population Cohort; IeDEA, International epidemiological Databases to Evaluate AIDS; ART, antiretroviral therapy.
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Ascertainment of NCD-speciﬁc outcomes is even more
challenging than ascertainment of all-cause mortality, often
requiring extensive diagnostic testing, which may have to be
adapted to the Sub-Saharan context. Renal, cancer, and other
NCD registries are rare.10,17 If unmeasured risk factors for
a given NCD, or the NCD itself, affect ascertainment, as with
death, partial NCD ascertainment will bias estimates of the
burden of NCDs at the population level and estimates of the
importance of risk factors for NCDs.
Further, even if death ascertainment is reasonably
complete, differential mortality patterns can result in mis-
leading conclusions.57 If deaths are treated as a competing
risk,65,66 the effect of HIV infection on NCDs may be under-
estimated because PLHIV experience higher mortality rates
than demographically and behaviorally similar individuals
without HIV, reducing the opportunity for NCDs to occur.
Similarly, beneﬁcial effects of ART on NCDs may be
obscured because ART reduces mortality. Although analytic
approaches that treat death as a censoring event avoid this
issue, these approaches estimate a quantity that may be harder
to interpret (an effect in the absence of mortality), and they
rely on the frequently unrealistic assumption that persons who
die would have had similar NCD outcomes had death been
prevented as persons (with similar measured characteristics)
who survive.
Measuring Exposure and Predictor Variables
Completeness and quality of measurement are also crucial
for exposure and predictor variables, and can be undermined by
signiﬁcant obstacles. First, few NCD risk factors are currently
recorded in HIV clinical databases. Augmentation of existing
databases with measurements of some risk factors, such as body
mass index (BMI), hematocrit, or proteinuria may be feasible
with minimal investment in some settings with developed
infrastructures.15,17 In other settings, however, the barriers to
incorporating even basic laboratory measurements may be
substantial.24
Second, measurement of self-reported behavioral risk
factors poses signiﬁcant challenges. For example, potential
participants in a Kenyan randomized trial who were HIV-
positive reported a high prevalence of hazardous and binge
drinking when screened by a separate investigator, whereas
a much lower prevalence was reported (particularly by
women) after screening was transferred to the clinic
nurse.67 On investigation, it was observed that the nurse
was asking women: “You don’t drink alcohol, do you?”
and asking men: “How much alcohol do you drink?”, intro-
ducing interviewer bias.68 Clinic staff and patients may be
fearful of violating societal norms, and patients may be
concerned that accurately reporting use of alcohol, non-
adherence to ART, or risky sexual behaviors might jeop-
ardize their access to treatment. Thus, measurements of
these risk factors may need to be independently validated,
for example, by phosphatidylethanol (PEth) testing for
alcohol intake.69
Third, to evaluate alternative care strategies, NCD
treatments and the key factors driving their use must be
measured. To the extent that HIV and NCD comorbidities
are treated through distinct health care systems, these data
will generally be missing from the HIV clinical databases.
Thus, sites in which HIV and NCD care services are
integrated have the potential to provide a research plat-
form.70,71 Such integration to date has been limited in SSA
but may accelerate.6,43,48,72 Further, in settings such as
South Africa, with unique patient identiﬁers and electronic
medical records, linkage of regional pharmacy or hospital
data with HIV cohort data may provide powerful supple-
mental data.
Measuring and Controlling for Confounders
Disentangling the effects of HIV infection and ART
on NCDs requires controlling for the fact that PLHIV
differ systematically from those without HIV, and persons
in care and on treatment differ systematically from
those off treatment. Although the use of appropriate
comparison groups, when available, can help to mitigate
confounding resulting from differences between HIV-
negative individuals and HIV-positive persons on ART
and not on ART, additional analytic adjustment is
generally necessary to control for residual differences in
risk factors. Further, individuals who receive a treatment
are often different from those who do not with respect to
factors that inﬂuence the outcome. For example, in a study
that aims to understand the long-term impact of ART on
development of diabetes, a subject’s BMI at baseline may
affect both initiation of ART and subsequent diabetes risk.
Standard techniques, such as contingency tables and
multivariable regression, as well as newer targeted data-
adaptive approaches can be used to adjust for such base-
line confounders.73,74
Control for confounding in the study of NCDs and
HIV is complicated further because exposures of interest
may change over time. In such cases, standard stratiﬁcation
or regression-based approaches to confounding adjustment
often break down.75 For example, time-varying factors such
as BMI may affect subsequent ART use and diabetes risk,
necessitating their control as confounders.15 However, these
confounders may themselves be on the causal pathway from
ART use to diabetes (or simply be affected by previous ART
use), preventing standard regression-based adjustment. Sim-
ilar concerns arise when attempting to disentangle the ef-
fects of ongoing viral replication and ART use on
depression from the effects of depression on adherence
and success of ART.16,76 When such time-dependent con-
founding occurs, alternative analytic methods, such as mar-
ginal structural models and corresponding inverse weighted
or targeted estimators are needed.75,77,78
Analytic adjustment for both baseline and time-
dependent confounding requires that the key adjustment
variables be measured well. Contextual knowledge
regarding the web of causality is essential to identifying
important confounders for a given question. This under-
standing can then guide data collection. In particular,
key variables affecting treatment decisions, and important
determinants or predictors of NCD outcomes, should
be captured.
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Prognostic and Mathematical Modeling
A prognostic model returns a predicted risk of some
outcome for an individual, based on that patient’s values
of multiple predictors. Missing data, the modeling
of continuous predictor variables, the complexity of the
model, and the checking of model assumptions are impor-
tant issues in this context.79 A range of methods are
available for constructing prognostic models, including
multivariable regression models and a range of “machine-
learning” approaches that automate the processes of
selecting predictor variables, modeling the functional
form of relationships between outcomes and contin-
uous predictors, and selecting an optimal degree of
model complexity.80,81
Formalized risk assessment using a prognostic model
(prediction index or rule) can improve the efﬁciency of
clinical care and research.79 Examples of prognostic mod-
els in HIV-positive populations include the model of mor-
tality in patients starting ART in SSA developed by
IeDEA24 (see www.iedea-sa.org for web calculator), and
the Veterans Aging Cohort Study (VACS) Index (http://
vacs.med.yale.edu).82,83 Potential applications to the pre-
vention and treatment of NCDs in LMICs include targeted
screening for metabolic risk factors and interventions such
as directing lipid lowering drugs to individuals at higher
risk,15,84 determining appropriate intervals for clinical
follow-up, assessing response to interventions, and plan-
ning for resource requirements.
Models do not need to include all possible risk factors
or biomarkers. Once several informative variables are
included, additional factors may not substantially improve
the predictive accuracy of the index. For example, in the
prognostic model of patients starting ART in SSA,24
the inclusion of either the CD4 cell count or the hemoglobin
and total lymphocyte count resulted in a model of similar
prognostic power that was not improved by including all
3 variables.
It is essential to demonstrate that a prognostic model
provides valid predictions outside the dataset and narrow
context in which it was developed. Cross-validation is
a method that uses multiple splits of the database, allowing
performance to be evaluated with data not used for building
the prognostic model.80,85 If the model is used in distinct
geographical areas, ideally external validation would also be
performed in these regions (geographic external validation).86
In assessing performance, a range of metrics is available. For
example, discrimination and calibration can be assessed by
calculating the c-statistic, risk, and net reclassiﬁcation index,
and plotting receiver operating curve and calibration
curves.87,88 Finally, when prognostic models are used as med-
ical interventions, their impact on health outcomes should
ideally be evaluated, either in randomized control trials or
using observational data.79
Mathematical modeling complements and informs
randomized control trials and observational research, pro-
viding a means of exploring potential impacts of many
different intervention strategies under a range of assump-
tions. Mathematical models have been widely used both in
the ﬁeld of HIV and NCDs, and will likely play a role in
answering several questions pertinent to NCDs in PLHIV.
The HIV Modeling Consortium provides a forum for
identifying questions, sharing models, data and expertise,
and rigorous review of modeling research.89
BUILDING RESEARCH CAPACITY
Expertise in study design, data collection and manage-
ment, and statistical analysis is needed to effectively carry out
the research discussed in this article.90 However, such capac-
ity is lacking in many settings in SSA. Although substantial
investments have been made in training a labor force with the
methodological expertise needed to address the challenge of
NCDs,91,92 expanded training opportunities for local investi-
gators, both in the form of on-the-job training and through
master’s and PhD level courses in biostatistics, epidemiology,
and information sciences, are often lacking in LMICs.
Further, development of a mentored and well-supported
research career path for LMIC investigators is needed to
ensure that investments in graduate-level training translate
into sustainable improvements in LMIC research capacity.
Both South–South collaborations such as the ALPHA net-
work (Analyzing Longitudinal Population-based HIV/AIDS
data on Africa),93 and collaborative research partnerships
between institutions in low-income and HICs can play
a role.94 Ultimately, however, building sustainable research
capacity requires a long-term commitment from donors, local
governments, and academic institutions in both low-income
and HICs.90,95
CONCLUSIONS AND RECOMMENDATIONS
We propose several recommendations (Box 1) to
improve the quality of data and analyses available to
inform the response to HIV and NCD comorbidity in
LMICs. First, published guidance for the transparent con-
duct and reporting of observational research should be con-
sidered.79,96,97 Second, optimal use of existing data sources
should be made, for example by linking routine HIV clin-
ical databases to laboratory databases, cancer registries,
pharmacy and hospitalization records, and electronic med-
ical record systems where available. In addition, for NCDs
with sufﬁciently high prevalence and incidence, substudies
can be added to large prospective studies that are address-
ing other questions. Third, data collection in existing stud-
ies and clinical databases should be strategically expanded
to obtain high-quality data on NCDs, key risk factors such
as smoking and hypertension, and key variables that inﬂu-
ence treatment decisions. Fourth, uninfected comparison
groups should be chosen carefully, taking into account es-
tablished risk factors. Fifth, analyses of observational data
should take into account key methodological challenges.
Sixth, collaborative research is required to overcome the
limited power of single studies and to validate prognostic
and mathematical models. Finally, local methodological
research capacity should be strengthened.
In conclusion, although this article has focused on
methodological challenges to observational research, many of
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these same challenges also directly undermine the delivery of
quality clinical care and public health interventions. Thus,
investment in overcoming these challenges, including improving
engagement in care, integrating health data systems, and
measuring key NCD risk factors has the potential to profoundly
beneﬁt the health of both HIV-positive and HIV-negative
populations in SSA and other LMICs.
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